We are live on ! Find out more
BLTE

Belite Bio
BLTE

8 hedge funds and large institutions have $25.4M invested in Belite Bio in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

14% more funds holding

Funds holding: 7 → 8 (+1)

0.03% less ownership

Funds ownership: 3.45% → 3.42% (-0.03%)

2% less capital invested

Capital invested by funds: $25.9M → $25.4M (-$472K)

25% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 4

Holders
8
Holders Change
+1
Holders Change %
+14.29%
% of All Funds
0.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
3
Reduced
4
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
+$21.2K
2
AWS
Atria Wealth Solutions
New York
+$10.1K
3
BlackRock
BlackRock
New York
+$5.65K
4
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$2.86K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$125K
2
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
-$94K
3
Morgan Stanley
Morgan Stanley
New York
-$29.2K
4
AA
ALPS Advisors
Colorado
-$9.15K

BLTE Hedge Fund Activity: Q1 2023 in Review

8 of the 6,284 institutional investors tracked by Wall St. Rank reported a position in Belite Bio (BLTE) for Q1 2023, worth a combined $25.4M — down 1.8% from $25.9M a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new BLTE positions and 0 closed out — a net gain of 1 holder — while 3 added to existing stakes and 4 trimmed.

The largest buyer was State Street, adding an estimated $21.2K. The largest seller was UBS Group, cutting an estimated $125K.

  • 8 institutional investors held Belite Bio (BLTE) as of Q1 2023, up from 7 in Q4 2022.
  • Funds reported $25.4M of Belite Bio stock for Q1 2023, down 1.8% quarter-over-quarter.
  • 1 fund opened new Belite Bio positions in Q1 2023 and 0 closed out, a net change of +1 holder.
  • The largest Belite Bio buyer in Q1 2023 was State Street, an estimated $21.2K added.
  • The largest Belite Bio seller in Q1 2023 was UBS Group, an estimated $125K sold.

Based on aggregated 13F filings for Q1 2023.